Jasper Therapeutics, Inc.
Clinical trials sponsored by Jasper Therapeutics, Inc., explained in plain language.
-
New hope for chronic hives: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety of a drug called briquilimab for people with chronic hives (urticaria). It includes 67 adults who already took part in a previous briquilimab study. Researchers will track side effects and how well the drug controls hives over time.
Phase: PHASE2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC
-
New hope for chronic hives sufferers: experimental drug briquilimab enters human trials
Symptom relief OngoingThis study tests an experimental drug called briquilimab in adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with usual antihistamines or the drug omalizumab. The trial has three parts, with some participants receiving the dru…
Phase: PHASE1, PHASE2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Symptom relief
Last updated May 14, 2026 12:03 UTC